Pre-meeting public consultation on proposals to amend the Poisons Standard - ACMS, ACCS & Joint ACMS-ACCS, March 2024

Closed 5 Feb 2024

Opened 5 Jan 2024

Contact

Medicines Scheduling

1800 020 653

medicines.scheduling@health.gov.au

Feedback updated 26 Jul 2024

We asked

From 5 January 2024 to 5 February 2024, we sought submissions from the public on scheduling proposals referred to the March 2024 meetings of the Advisory Committees on Medicines and Chemicals Scheduling. Respondents could indicate their support or opposition to the proposed amendments with or without a written response.

You said

We received 124 submissions in response to the pre-meeting public notice for March 2024. The breakdown of the responses is provided below:

For cytisine, a total of 41 responses were received, 3 in opposition, 2 in partial support and 36 in full support of the proposed interim decision.

For dextromethorphan, a total of 14 responses were received, 5 in opposition, 2 in partial support and 7 in full support of the proposed interim decision.

For dihydocoodeine, a total of 12 responses were received, 4 in opposition, and 8 in full support of the proposed interim decision.

For ethylmorphine, a total of 10 responses were received, 2 in opposition, 2 in partial support and 6 in full support of the proposed interim decision.

For ethyl lactyl retinoate, a total of 9 responses were received, 2 in opposition, 1 in partial support and 6 in full support of the proposed interim decision.

For niclosamide, a total of 6 responses were received, 1 in partial support and 5 in full support of the proposed interim decision.

For oxytetracycline, a total of 23 responses were received, 19 in opposition, and 4 in full support of the proposed interim decision.

For tranexamic acid, a total of 9 responses were received, 2 in opposition, and 7 in full support of the proposed interim decision.

We did

The Delegate considered all responses prior to making an interim decision on these proposals. The interim decisions on the proposed amendments to the Poisons Standard were published on 26 July 2024.

 

 

Published responses

View submitted responses where consent has been given to publish the response.

Overview

Scheduling amendments referred to expert advisory committee

This consultation is for applications and delegate initiated proposals to amend the Poisons Standard. The scheduling amendments and any submissions received will be considered at the March 2024 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS).

The closing date for this consultation is close of business 5 February 2024. All submissions received by the deadline will be considered by the delegate before they make an interim decision.

The proposals under consultation are detailed in the public notice of March 2024. 

Substances for which public comment is sought:
 

ACMS:

  • Cytisine
  • Dextromethorphan
  • Dihydrocodeine
  • Ethylmorphine

ACCS:

  • Ethyl lactyl retinoate
  • Niclosamide

Joint meeting of ACMS-ACCS:

  • Oxytetracycline
  • Tranexamic acid

What happens next

All public submissions will be published on the TGA website at Public submissions on scheduling matters, unless marked confidential or indicated otherwise in the submission information (see Privacy and your Personal information).

Public submissions are an important part of the process for amending the Poison Standard, and are published on the TGA website using the consultation hub.  Submissions by the public may not reflect the views of the Department of Health and Aged Care or TGA.  Published submissions should not be taken as being endorsed by the Department or TGA.

Following consideration of public submissions received before the closing date and advice from the expert advisory committee/s, decisions on the proposed amendments are anticipated to be published as interim decisions on the TGA website: Scheduling delegate's interim decisions & invitations for further comment at a later date. 

Audiences

  • Anyone from any background

Interests

  • Policy Development